###begin article-title 0
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia 
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist. 
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 481 491 481 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF). Subsequent analysis has shown that constitutive activation of the JAK-STAT signal transduction pathway is an important pathogenetic event in these patients, and that enzymatic inhibition of JAK2V617F may be of therapeutic benefit in this context. However, a significant proportion of patients with ET or MF are JAK2V617F-negative. We hypothesized that activation of the JAK-STAT pathway might also occur as a consequence of activating mutations in certain hematopoietic-specific cytokine receptors, including the erythropoietin receptor (EPOR), the thrombopoietin receptor (MPL), or the granulocyte-colony stimulating factor receptor (GCSFR). 
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 273 282 273 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAKV617F-</italic>
###xml 839 841 839 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 634 640 <span type="species:ncbi:10090">murine</span>
DNA sequence analysis of the exons encoding the transmembrane and juxtamembrane domains of EPOR, MPL, and GCSFR, and comparison with germline DNA derived from buccal swabs, identified a somatic activating mutation in the transmembrane domain of MPL (W515L) in 9% (4/45) of JAKV617F-negative MF. Expression of MPLW515L in 32D, UT7, or Ba/F3 cells conferred cytokine-independent growth and thrombopoietin hypersensitivity, and resulted in constitutive phosphorylation of JAK2, STAT3, STAT5, AKT, and ERK. Furthermore, a small molecule JAK kinase inhibitor inhibited MPLW515L-mediated proliferation and JAK-STAT signaling in vitro. In a murine bone marrow transplant assay, expression of MPLW515L, but not wild-type MPL, resulted in a fully penetrant myeloproliferative disorder characterized by marked thrombocytosis (Plt count 1.9-4.0 x 10 12/L), marked splenomegaly due to extramedullary hematopoiesis, and increased reticulin fibrosis. 
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 98 108 98 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 430 440 430 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in patients with JAK2V617F-negative MF. The bone marrow transplant model of MPLW515L-mediated myeloproliferative disorders (MPD) exhibits certain features of human MF, including extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation. Further analysis of positive and negative regulators of the JAK-STAT pathway is warranted in JAK2V617F-negative MPD. 
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 523 531 <span type="species:ncbi:9606">patients</span>
Myelofibrosis with myeloid metaplasia (MF) is one of a group of chronic blood disorders, known as chronic myeloproliferative disorders. These disorders sometimes turn into acute leukemia. The main abnormality in myelofibrosis is for the bone marrow to become filled with fibrous (scar) tissue (hence the name myelofibrosis), which stops it from producing normal blood cells efficiently. In addition, the white blood cells that remain are abnormal (that is, metaplastic). The clinical effect of these abnormalities are that patients are anemic (they have low numbers of red cells), are more likely to get infections because of the abnormal white cells which cannot fight infections normally, and may bleed more easily because of a lack of the platelets that help the blood to clot. Scientists who study this disorder believe that the disease starts from just one abnormal cell, which divides to replace all the other cells-that is, all the abnormal cells are part of one clone.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
In two similar diseases, polycythemia vera (in which the bone marrow produces too many red blood cells) and essential thrombocytosis (in which the bone marrow produces too many platelets), and in some patients with MF, scientists have found genetic changes which seem to trigger these diseases. However, there are some patients with MF in which no abnormal gene has been found. The scientists here wanted to look at other genes to see if they could find any changes that might trigger MF.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 383 386 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 639 642 639 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 1060 1064 <span type="species:ncbi:10090">mice</span>
###xml 1070 1074 <span type="species:ncbi:10090">mice</span>
###xml 1126 1132 <span type="species:ncbi:9606">humans</span>
They decoded the DNA sequence of three genes that are known to be involved in how blood cells develop for 45 patients with MF. They looked at DNA from white blood cells, and also from normal cheek cells for comparison. They found that in four of the 45 patients the DNA in the bone marrow, but not the cheek, carried a mutation in a gene for the thrombopoietin receptor (also called MPL). This gene is necessary for the cells that make platelets to grow correctly. The mutation was not present in any samples from patients with diseases related to MF, nor in 270 normal samples. The mutation that was identified was at position 515 in the MPL gene sequence, hence the name MPLW515L-the W and the L are the shorthand way of indicating exactly which change occurred. The change meant that the gene became abnormally active. The researchers tested the effect of the abnormal gene by putting it into cells grown in culture in the laboratory; they found that it made the cells grow more than was normal. In addition, when cells with the abnormal gene were put into mice, the mice developed a blood disorder similar to that seen in humans with MF. 
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 132 135 132 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
It seems likely that the genetic change that has been identified here is responsible for the MF that develops in some patients. The MPL gene is known to be part of a pathway of genes that control how certain blood cells develop. However, it is not yet clear exactly how the genetic change found here causes the blood cells to grow abnormally, or how it causes the other clinical effects of MF. Further work will also need to be done to see if it is possible to develop drugs that can act on this gene mutation, or on the other genes that it affects so as to return the cells to normal. 
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at . 
###end p 18
###begin p 19
* MedlinePlus, a Web site of the US National Library of Health, has pages of information on 
###end p 19
###begin p 20
###xml 93 101 <span type="species:ncbi:9606">patients</span>
* The National Cancer Institute, which funds research into many cancers, has information for patients on , including information on clinical trials 
###end p 20
###begin p 21
###xml 27 35 <span type="species:ncbi:9606">patients</span>
* The  has information for patients with myelofibrosis and related diseases 
###end p 21
###begin p 22
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Activation of JAK-STAT signaling via a mutation - MPLW515L- in the thrombopoietin receptor seems to have a role in the pathogenesis of some patients with myelofibrosis.
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b001">1</xref>
###xml 420 429 420 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b002">2</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b006">6</xref>
###xml 592 601 592 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b007">7</xref>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b008">8</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b009">9</xref>
###xml 851 852 851 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b004">4</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b010">10</xref>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b002">2</xref>
###xml 1045 1046 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b004">4</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b011">11</xref>
###xml 1199 1209 1199 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 971 977 <span type="species:ncbi:10090">murine</span>
The BCR-ABL negative chronic myeloproliferative disorders (MPD) include polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF) [ 1]. Although clonal hematopoiesis was observed in these disorders more than three decades ago, the molecular etiology of these disorders was not known until recently when several groups reported a somatic mutation in the JAK2 tyrosine kinase ( JAK2V617F) in most patients with PV and in a subset of patients with ET and MF [ 2- 6]. Recent estimates using high sensitivity mutation detection techniques indicate that JAK2V617F is present in  95-100% of PV, 60%-70% of ET, and 50% of MF [ 7, 8]. JAK2V617F is a constitutively active tyrosine kinase [ 9] that activates downstream signal transduction pathways and transforms hematopoietic cells to cytokine-independent growth [ 4, 10], and these cells are sensitive to a small molecule JAK Inhibitor [ 2]. In addition, expression of JAK2V617F in a murine bone marrow transplant assay results in a MPD most similar to PV [ 4, 11]. These data indicate that constitutive activation of JAK-STAT signaling by the mutant JAK2V617F kinase plays a central role in the pathogenesis of JAK2V617F-positive PV, ET, and MF. 
###end p 24
###begin p 25
###xml 36 45 36 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 174 184 174 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 276 285 276 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 381 391 381 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b007">7</xref>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 540 548 <span type="species:ncbi:9606">patients</span>
Despite the recent discovery of the JAK2V617F allele, questions remain regarding the molecular pathogenesis of PV, ET, and MF. In particular, the mutation(s) responsible for JAK2V617F-negative ET and MF remain to be identified. Although more sensitive techniques can identify JAK2V617F mutations in a small proportion of clonal cells, we recently demonstrated that the majority of JAK2V617F-negative ET and MF patients have clonal granulocytes [ 7], suggesting that alternative mutation(s) result in clonal granulopoiesis in this subset of patients. 
###end p 25
###begin p 26
###xml 21 31 21 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK1</italic>
###xml 349 353 349 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK3</italic>
###xml 355 359 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYK2</italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT3</italic>
###xml 371 376 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAT5</italic>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b012">12</xref>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
We hypothesized that JAK2V617F-negative patients with MPD might have mutations involving other components of the JAK-STAT signal transduction pathway that include cytokine receptors, other JAK family members, or STAT family members. Screens for additional mutations in other JAK-STAT signaling intermediates in this clinical context including JAK1, JAK3, TYK2, STAT3, or STAT5 have been negative [ 12]. 
###end p 26
###begin p 27
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b010">10</xref>
###xml 603 613 603 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPOR</italic>
###xml 799 802 799 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b013">13</xref>
###xml 957 961 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPOR</italic>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b014">14</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b015">15</xref>
###xml 1120 1121 1120 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b002">2</xref>
###xml 1281 1291 1281 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 1340 1350 1340 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPOR, MPL,</italic>
###xml 1354 1359 1354 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCSFR</italic>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
###xml 992 1000 <span type="species:ncbi:9606">patients</span>
###xml 1102 1109 <span type="species:ncbi:9606">patient</span>
###xml 1168 1176 <span type="species:ncbi:9606">patients</span>
###xml 1267 1275 <span type="species:ncbi:9606">patients</span>
We have recently shown that expression of a homodimeric type I cytokine receptor, such as the erythropoietin receptor (EPOR), the thrombopoietin receptor (MPL), or the granulocyte-colony stimulating factor receptor (GCSFR), is required for JAK2V617F-mediated transformation of hematopoietic cells and for activation of downstream signaling [ 10]. These data suggested the possibility that mutations in the regions of these cytokine receptors that are critical for receptor dimerization (transmembrane domain) and for JAK2 binding (juxtamembrane domain) might lead to activation of JAK-STAT signaling in JAK2V617F-negative MPD. Indeed, such mutations in the context of EPOR have been identified in rare familial cases of polycythemia, though these have not been reported in acquired MPD. Heretofore, MPL has been sequenced in a small cohort of patients with MF and ET, but no mutations were identified [ 13], and multiple groups have reported the absence of EPOR mutations in small numbers of patients with PV [ 14, 15]. High throughput DNA sequence analysis and the collection of a large number of MPD patient samples [ 2] has enabled evaluation of a larger series of patients for mutations in candidate genes, including cytokine receptors. We therefore investigated patients with JAK2V617F-negative MPD for somatic activating mutations in EPOR, MPL, or GCSFR. 
###end p 27
###begin title 28
Methods
###end title 28
###begin title 29
Sample Collection
###end title 29
###begin p 30
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b002">2</xref>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
Granulocyte DNA samples and matched normal DNA samples were collected from patients with PV, ET, and MF who were enrolled in the Harvard Myeloproliferative Disorders Study as previously described [ 2]. Additional samples from patients with MF were collected on a separate Dana-Farber Cancer Institute protocol. All subjects provided informed consent on protocols approved by the Dana-Farber Cancer Institute Institutional Review Board. 
###end p 30
###begin title 31
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
DNA Sequence Analysis and Genotyping for MPLW515L
###end title 31
###begin p 32
###xml 56 66 56 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL, EPOR,</italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCSFR</italic>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b002">2</xref>
###xml 190 198 190 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st001">Table S1</xref>
###xml 880 881 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b002">2</xref>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
PCR amplification and DNA sequencing of select exons of MPL, EPOR, and GCSFR was performed using M13-tailed primers as previously described [ 2], and specific primer sequences are listed in Table S1. Sequence analysis of bidirectional sequence traces was performed using Mutation Surveyor version 2.28 (SoftGenetics, State College, Pennsylvania, United States). Candidate mutations were reamplified and sequenced from original DNA for independent verification, and sequence analysis of buccal DNA was performed to ascertain whether non-synonymous mutations were constitutional or somatic in origin. Identity between granulocyte and buccal DNA for individual patients was confirmed using eight informative synonymous single nucleotide polymorphisms. Genotypic analysis of the HapMap panel of normal patients was performed using a mass spectrometric assay as previously described [ 2]. 
###end p 32
###begin title 33
Expression Vectors and Cell Culture
###end title 33
###begin p 34
###xml 114 122 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 1126 1127 1126 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 334 340 <span type="species:ncbi:9913">bovine</span>
###xml 780 786 <span type="species:ncbi:10090">murine</span>
The MSCV-MPL-Neo and MSCV-MPL-IRES-EGFP retroviral vectors were generously provided by W. Tong and H. Lodish. The MPLW515L mutation was generated using site-directed mutagenesis (Quickchange-XL, Stratagene, La Jolla, California, United States) and confirmed by full-length DNA sequencing. 293T cells were grown in DMEM with 10% fetal bovine serum (FBS). Transient co-transfection of 293T cells and generation of retroviral supernatant were performed using Fugene (Roche, Nutley, New Jersey, United States) according to manufacturer's guidelines. 32D and Ba/F3 cells were grown in RPMI medium 1640 containing 10% FBS and 10% WEHI-3B cell supernatant as a source of IL3. UT7 cells were grown in IMDM medium supplemented with 10% FBS and GMCSF (1 ng/mL). 32D cells, Ba/F3 cells, and murine bone marrow cells were transduced with viral supernatant, and UT7 cells were transduced by electroporation (Amaxa, Gaithersburg, Maryland, United States). Cells were then selected in G418 (1mg/mL). To assess for factor-independent growth and for thrombopoietin hypersensitivity, cells were first washed three times in PBS, and then 1 x 10 5 viable cells/mL were resuspended in appropriate cytokine-free media or in media containing different concentrations of thrombopoietin (Sigma, St. Louis, Missouri, United States) as noted. The number of viable cells was determined by trypan blue exclusion. 
###end p 34
###begin title 35
Western Blot Analysis
###end title 35
###begin p 36
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b016">16</xref>
Cells were collected and lysed in lysis buffer and separated by electrophoresis as described previously [ 16]. Nitrocellulose membrane was blocked in TBST/5% milk and incubated with one of the following antibodies: anti-pSTAT5 (Cell Signaling, Beverly, Massachusetts, United States), anti-pSTAT3 (Cell Signaling), anti-pERK (Cell Signaling), anti-pAKT (Cell Signaling), anti-pTYK2 (Cell Signaling), or anti-pJAK2 (Cell Signaling). For loading controls, blots were stripped and reprobed using anti-JAK2 (Santa Cruz Biotechnology, Santa Cruz, California, United States), anti-TYK2 (Santa Cruz Biotechnology), anti-STAT5 (Santa Cruz Biotechnology), anti-STAT3 (Cell Signaling), anti-ERK (Cell Signaling), anti-AKT (Cell Signaling), and anti-TYK2 (Santa Cruz Biotechnology) antibodies as appropriate. 
###end p 36
###begin title 37
JAK Inhibitor Assays
###end title 37
###begin p 38
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b016">16</xref>
For cell-proliferation assays, 32D cells stably expressing FIP1L1-PDGFRA [ 16] and MPLW515L were grown in RPMI/10% FBS and then incubated with appropriate concentrations of JAK Inhibitor I (Calbiochem, San Diego, California, United States) for 72 hours. 32D cells expressing MPLWT were grown in RPMI/10%FBS/mTPO in the presence of JAK Inhibitor I. The number of viable cells was determined using CellTiter 96 Aqueous One Cell Proliferation Assay (Promega, San Luis Obispo, California, United States). For Western blotting, cell lines were incubated in the presence of JAK Inhibitor I for four hours, and phosphorylation of relevant proteins was assessed as described above. 
###end p 38
###begin title 39
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine Bone Marrow Transplant Assay
###end title 39
###begin p 40
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b017">17</xref>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 841 842 841 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 891 892 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1205 1206 1205 1206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
###xml 1134 1138 <span type="species:ncbi:10090">mice</span>
###xml 1213 1218 <span type="species:ncbi:10090">mouse</span>
The murine bone marrow transplant assay was performed as previously described [ 17]. MSCV retroviral supernatants were titered by determining the percentage of GFP positive cells 48 hours after infection of Ba/F3 and 32D cells (1 mL supernatant used to infect 1 x 10 6 cells). MPLWT and MPLW515L retroviral supernatants were able to reproducibly infect 40%-60% of Ba/F3 and 32D cells as assessed by flow cytometry. Balb/C donor mice were treated with 5-Florouracil (150 mg/kg) seven days prior to bone marrow harvest. Bone marrow cells were harvested from donor mice, treated with red blood cell lysis buffer and cultured for 24 hours in transplantation medium (RPMI + 10% FBS + 6 ng/mL IL-3, 10 ng/mL IL-6, and 10 ng/mL stem-cell factor (SCF)). Cells were treated by spin infection with retroviral supernatants (1 mL supernatant per 4 x 10 6 cells, plus polybrene) and centrifuged at 1,800 g for 90 minutes. The spin infection was repeated 24 hours later. The cells were then washed and resuspended in Hank's balanced salt solution, and injected into lateral tail veins of lethally irradiated (2 x 4.5 Gy [450 rad]) Balb/C recipient mice (Taconic, Germantown, New York, United States) at 0.5 to 1.0 x 10 6 cells/mouse. Animals were humanely killed when they had palpable splenomegaly or were moribund. Animals transplanted with bone marrow that was transduced with MPLWT viral supernatant were killed at the time of manifestation of MPLW515L disease for endpoint analysis. 
###end p 40
###begin title 41
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Analysis
###end title 41
###begin p 42
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b018">18</xref>
Peripheral blood was collected from the retro-orbital cavity using EDTA-treated glass capillary tubes and analyzed by automated complete and differential blood cell counts and blood smears (Wright-Giemsa stained). Single-cell suspensions of spleen and bone marrow were prepared by pressing tissue through a cell strainer, followed by red blood cell lysis. For histopathology, tissues were fixed in formalin and then embedded in paraffin for histology analysis as previously described [ 18]. 
###end p 42
###begin p 43
###xml 50 56 <span type="species:ncbi:9913">bovine</span>
###xml 122 128 <span type="species:ncbi:9913">bovine</span>
For flow cytometry, cells were washed in PBS + 1% bovine serum albumin and stained with monoclonal antibodies in PBS + 1% bovine serum albumin for 30 minutes on ice. Antibodies used were allophycocyanin-conjugated Gr-1, B220, Ter119, CD8, cKit; and phycoerythrin-conjugated Mac-1, CD19, CD71, CD4, CD41 (BD Pharmingen, San Diego, California, United States). Flow cytometry analysis was performed on a FACSCalibur instrument (BD Biosciences, San Jose, California, United States) and analyzed with CellQuest software (BD Biosciences). Viability was assessed by incubating cells with 7-AAD (7-amino-actinomycin D) (BD Pharmingen) for five minutes prior to flow cytometry. Cells were gated for viability (using forward/side scatter and 7-AAD) and GFP positivity, and 10,000 events were analyzed from this subset for marker expression.
###end p 43
###begin p 44
###xml 90 98 <span type="species:ncbi:9606">Children</span>
The study protocol was reviewed and approved by the Boston (Massachusetts, United States) Children's Hospital Animal Care and Use Committee.
###end p 44
###begin title 45
In Vitro Colony-Forming Assays
###end title 45
###begin p 46
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 758 763 <span type="species:ncbi:10090">mouse</span>
Myeloid colony-forming assays were performed in methylcellulose-based medium (M3434) containing 3U/mL erythropoietin, 10 ng/mL IL-3, 10 ng/mL IL-6, and 50 ng/mL SCF, and in M3231 medium containing no additional cytokines, as per manufacturer's protocols (StemCell Technologies, Vancouver, British Columbia, Canada). Cells were plated at 1.5 x 10 4 cells per dish for bone marrow cells and 5 x 10 4 cells per dish for spleen cells, in duplicate. Plates were incubated at 37 degreesC for seven days. Colonies were scored by morphology, and representative colonies were confirmed by Wright-Giemsa stained slides of colony cytospins. Graphs represent total number of colonies counted for three representative mice in each group, with two plates counted for each mouse. Megakaryocyte colony-forming assays were performed in collagen-containing medium (MegaCult-C; StemCell Technologies) containing TPO, IL-11, IL-3, and IL-6 for seven days. Slides were fixed and stained for six hours with acetylcholine iodide (Sigma) as per MegaCult protocol, and were counterstained with Harris hematoxylin solution (Sigma) as per manufacturer's protocol. 
###end p 46
###begin p 47
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b019">19</xref>
###xml 180 183 <span type="species:ncbi:10116">rat</span>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
To assess megakaryocyte ploidy, bone marrow cells were cultured for four days in RPMI/10% FBS containing 50 ng/mL mTPO and 10 mg/mL SCF. Cells were collected and stained with FITC-rat anti-mouse CD41 antibody (BD Biosciences), followed by 50 ug/mL propidium iodide in 0.1% sodium citrate buffer with 50 ug/mL RNAase, as previously described [ 19]. Data was acquired on a FACSCalibur (BD Biosciences) and analyzed with CellQuest software. 
###end p 47
###begin title 48
Results
###end title 48
###begin title 49
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</italic>
MPLW515L Mutation in JAK2 V617F-Negative MPD 
###end title 49
###begin p 50
###xml 60 72 60 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPOR, GCSFR,</italic>
###xml 77 80 77 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 87 96 87 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 122 131 122 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPOR</italic>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCSFR,</italic>
###xml 299 302 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 391 399 391 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 427 435 427 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g001">Figure 1</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g001">1</xref>
###xml 474 484 474 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 530 538 530 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 602 610 602 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V617F</italic>
###xml 660 661 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 676 677 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 788 796 788 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 812 820 812 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g001">Figure 1</xref>
###xml 856 864 856 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 965 968 965 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 976 986 976 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 1091 1099 1091 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b020">20</xref>
###xml 1292 1299 1292 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515</italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 592 600 <span type="species:ncbi:9606">patients</span>
###xml 684 691 <span type="species:ncbi:9606">patient</span>
###xml 1005 1013 <span type="species:ncbi:9606">patients</span>
We sequenced the transmembrane and juxtamembrane domains of EPOR, GCSFR, and MPL in 15 JAK2V617F-negative MF patients, 16 JAK2V617F-negative patients with ET, and 4 JAK2V617F-negative PV patients. Although we found no mutations in EPOR or GCSFR, we identified a guanine to thymidine substitution in MPL at nucleotide 1544 which results in a tryptophan to leucine substitution at codon 515 ( MPLW515L) in two patients with MF ( Figure 1A and 1B). Sequencing of 30 additional JAK2V617F-negative MF samples identified two additional MPLW515L-positive samples, for a total frequency of 4/45 (9%) patients. MPLW515L was not detected in any JAK2 V617F-negative ET ( n = 50) or PV ( n = 10) patient samples. Sequence analysis of matched normal DNA derived from buccal swabs did not identify the MPLW515L substitution ( Figure 1A, upper trace), demonstrating that MPLW515L is a somatic mutation in hematopoietic cells. Sequence analysis of the entire open reading frame of MPL in all JAK2V617F-negative ET and MF patients did not reveal additional somatic mutations. To assess the prevalence of the MPLW515L allele in the general population, we genotyped a standard panel of 270 samples collected by the International HapMap Consortium [ 20]. All 270 HapMap samples were homozygous for the wild-type MPLW515 allele. 
###end p 50
###begin p 51
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 306 315 306 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L-</italic>
###xml 467 476 467 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L-</italic>
###xml 589 598 589 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L-</italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 607 615 <span type="species:ncbi:9606">patients</span>
No significant clinical differences were observed between MPLW515L-positive versus MPLW515L-negative patients with MF with regard to median age at presentation and to disease duration, though the statistical power of this analysis was limited by the small number of patients with MF in our cohort. For all MPLW515L-positive MF patients for which bone marrow histopathology was available (3/4), marked megakaryocyte hyperplasia was noted. In addition, two of the four MPLW515L-positive patients exhibited leukocytosis and thrombocytosis at the time of disease presentation. One of the four MPLW515L-positive patients had a rapidly progressive clinical course, with death two years after initial presentation from complications related to MF. 
###end p 51
###begin title 52
Functional Analysis of MPLW515L and Wild-Type MPL
###end title 52
###begin p 53
###xml 136 144 136 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g001">Figure 1</xref>
###xml 299 307 299 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g001">Figure 1</xref>
###xml 512 520 512 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g001">Figure 1</xref>
###xml 666 674 666 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g002">Figure 2</xref>
###xml 680 681 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g002">2</xref>
###xml 732 740 732 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g002">Figure 2</xref>
###xml 746 747 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g002">2</xref>
In cell culture assays, expression of MPLW515L, but not MPLWT, conferred cytokine-independent growth to 32D, UT7, or Ba/F3 cell lines ( Figure 1C and unpublished data). Western blotting demonstrated constitutive phosphorylation of the JAK/STAT signaling proteins, including JAK2, STAT3, and STAT5 ( Figure 1D). Downstream targets of this pathway were also activated, with constitutive phosphorylation of p42/44 ERK and AKT in 32D MPLW515L cells consistent with activation of the RAS/MAPK and PI3K/AKT pathways ( Figure 1D). In addition, expression of MPLW515L in 32D and UT7 cells resulted in hypersensitivity to TPO compared with MPLWT as assessed by cell growth ( Figure 2A and 2B) and by Western blotting after TPO stimulation ( Figure 2C and 2D). 
###end p 53
###begin title 54
###xml 2 8 <span type="species:ncbi:10090">Murine</span>
A Murine Model for MPLW515L-Induced Myeloproliferative Disease
###end title 54
###begin p 55
###xml 441 449 441 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g003">Figure 3</xref>
###xml 520 522 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 571 572 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 578 586 578 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g003">Figure 3</xref>
###xml 777 785 777 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g003">Figure 3</xref>
###xml 791 792 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g003">3</xref>
###xml 911 919 911 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g003">Figure 3</xref>
###xml 78 84 <span type="species:ncbi:10090">murine</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 733 737 <span type="species:ncbi:10090">mice</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
To assess the in vivo effects of the MPLW515L mutant receptor, we developed a murine model of MPLW515L-induced myeloproliferative disease. Bone marrow cells were transduced with MSCV-IRES-EGFP vectors containing MPLWT or MPLW515L and transplanted into lethally irradiated Balb/C mice. MPLW515L-transduced animals, but not MPLWT-transduced animals, developed a short latency (median latency = 18 days post BMT), fully penetrant, lethal MPD ( Figure 3A) notable for marked thrombocytosis (mean platelet count = 3.414 x 10 12/L) as well as leukocytosis (mean WBC = 201 x 10 9/L) ( Figure 3B). There was no significant difference in the hematocrit of MPLW515L mice compared with MPLWT mice. At the time of sacrifice, MPLW515L-expressing mice showed splenomegaly and hepatomegaly ( Figure 3C and 3D), and staining of bone marrow demonstrated increased reticulin fibrosis in MPLW515L, but not MPLWT-expressing mice ( Figure 3E). 
###end p 55
###begin p 56
###xml 130 138 130 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 372 380 372 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">4</xref>
###xml 711 719 711 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">4</xref>
###xml 819 827 819 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 1156 1164 1156 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 1170 1171 1170 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">4</xref>
###xml 1253 1261 1253 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 1267 1268 1267 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">4</xref>
###xml 1525 1533 1525 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">Figure 4</xref>
###xml 1539 1540 1539 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g004">4</xref>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
Histopathology analysis was consistent with the presence of a MPD in MPLW515L-expressing mice, but not in MPLWT-expressing mice ( Figure 4). Examination of peripheral blood smears from MPLW515L mice revealed marked thrombocytosis and leukocytosis composed of predominantly mature myeloid elements admixed with occasional to frequent numbers of nucleated erythroid cells ( Figure 4A and 4B). Compared with MPLWT animals, MPLW515L mice demonstrated markedly hypercellular bone marrow with a predominance of maturing myeloid forms and with increased numbers of atypical and dysplastic megakaryocytes which could be found in frequent clusters and exhibited emperipolesis of neutrophils in megakaryocyte cytoplasm ( Figure 4C and 4D). Spleens from MPLW515L mice revealed complete effacement of normal splenic architecture ( Figure 4E), with a prominent expansion of red pulp composed of an admixture of maturing myeloid and erythroid elements, and numerous abnormal megakaryocytes. By comparison, spleens from MPLWT animals displayed a relative preservation of normal splenic architecture with only a mild expansion of red pulp by maturing erythroid elements ( Figure 4F and 4H) that were also noted in small, focal clusters in the livers of these animals ( Figure 4J and 4L). In contrast, extensive extramedullary hematopoiesis was observed in the livers of MPLW515L animals, which was composed primarily of maturing erythroid elements with frequent atypical megakaryocytes and relatively fewer numbers of mature myeloid cells ( Figure 4I and 4K). 
###end p 56
###begin p 57
###xml 224 232 224 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">Figure 5</xref>
###xml 429 437 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">Figure 5</xref>
###xml 573 581 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">Figure 5</xref>
###xml 791 799 791 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">Figure 5</xref>
###xml 805 806 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">5</xref>
###xml 1027 1035 1027 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">Figure 5</xref>
###xml 1246 1254 1246 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g005">Figure 5</xref>
###xml 725 729 <span type="species:ncbi:10090">mice</span>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
Consistent with the histopathologic findings, flow cytometry analysis of MPLW515L bone marrow cells demonstrated an  4-fold increase in Mac1+/Gr1+ mature myeloid cells as compared with bone marrow cells from MPLWT animals ( Figure 5A, upper panels). These findings were also reflected in the splenocyte populations examined from MPLW515L animals that revealed a nearly 10-fold increase in Mac1+/Gr1+ cells versus MPLWT spleens ( Figure 5B, upper panels). Further analysis of MPLWT and MPLW515L spleen and bone marrow cells demonstrated a significant erythroid population ( Figure 5B, middle panel) in both sets of animals, although a shift to a more immature erythroid population was observed in MPLW515L compared with MPLWT mice as reflected by an  2-fold increase in CD71+/Ter119- cells ( Figure 5A and 5B, middle panels). The marked increase in megakaryocytes seen in the histopathology of MPLW515L mice was corroborated by an  15-fold increase in the percentage of CD41+ cells in MPLW515L bone marrow compared with MPLWT ( Figure 5A, bottom panels). Similar increases were observed in MPLW515L spleen cells compared with MPLWT with an  30-fold increase in the proportion of CD41+ cells observed in MPLW515L spleen cells compared with MPLWT ( Figure 5B, bottom panels). Analysis of B cells demonstrated a proportionate decrease in B220 positive cells in MPLW515L bone marrow and spleen (unpublished data). There was no difference in CD4/CD8+ or c-Kit positive cell populations between MPLW515L and MPLWT bone marrow and spleen cells (unpublished data). 
###end p 57
###begin title 58
MPLW515L Confers a Proliferative Advantage to Bone Marrow and Spleen Cells
###end title 58
###begin p 59
###xml 327 335 327 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 429 437 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 521 529 521 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 728 736 728 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 936 944 936 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 950 951 950 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">6</xref>
###xml 1103 1111 1103 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 1143 1151 1143 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 1373 1381 1373 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 1387 1388 1387 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">6</xref>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
###xml 1366 1370 <span type="species:ncbi:10090">mice</span>
Megakaryocyte colony-forming assays of bone marrow cells derived from MPLW515L- and MPLWT-expressing mice demonstrated a similar number of megakaryocyte colony-forming units, although there was a marked increase in megakaryocyte colony-forming units formed from spleen cells from MPLW515L-expressing mice compared with MPLWT ( Figure 6A). In addition, acetylcholinesterase staining demonstrated MPLW515L megakaryocyte colonies ( Figure 6B, left picture) that were significantly larger than MPLWT megakaryocyte colonies ( Figure 6B, right picture). The difference in megakaryocyte colony growth and morphology was not explained by a difference in ploidy of megakaryocyte cells in MPLW515L compared with MPLWT bone marrow cells ( Figure 6C). Perhaps the most striking finding was the ability of bone marrow or spleen cells derived from MPLW515L animals, but not MPLWT, to grow in methylcellulose culture in the absence of any cytokines ( Figure 6D and 6E). There was also an increase in the number of myeloid colonies in methylcellulose supplemented with cytokines from MPLW515L-expressing spleen cells ( Figure 6E), but not bone marrow cells ( Figure 6D), consistent with a shift in hematopoiesis from the bone marrow to the spleen in MPLW515L-expressing mice. There was no difference in the distribution of myeloid colonies grown from MPLWT- and MPLW515L-expressing mice ( Figure 6D and 6E). 
###end p 59
###begin title 60
JAK Kinase Inhibition Results in Inhibition of MPLW515L-Induced Proliferation and Signal Transduction
###end title 60
###begin p 61
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b021">21</xref>
###xml 183 191 183 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g007">Figure 7</xref>
###xml 345 353 345 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g007">Figure 7</xref>
Treatment of 32D MPLW515L or 32D MPLWT cells but not 32D FIP1L1-PDGFRA cells with a small molecule JAK kinase inhibitor [ 21] resulted in a dose-dependent inhibition of cell growth ( Figure 7A). Dose-dependent inhibition of phosphorylation of STAT3, ERK, and AKT was observed in 32D MPLW515L and MPLWT cells but not in 32D FIP1L1-PDGFRA cells ( Figure 7B; unpublished data). These data indicate that MPLW515L-mediated proliferation and activation of JAK-STAT signaling is sensitive to inhibition with a small molecule JAK kinase inhibitor. 
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 77 80 77 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 108 118 108 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 760 770 760 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 783 792 783 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L-</italic>
###xml 353 359 <span type="species:ncbi:10090">murine</span>
In this report we describe a somatic mutation in the transmembrane region of MPL ( MPLW515L) in a subset of JAK2V617F-negative MF. Expression of MPLW515L transforms hematopoietic cells to cytokine-independent proliferation, and results in constitutive activation of JAK-STAT signaling. The relevance of this mutation is underscored by its effect in the murine bone marrow transplant assay, as expression of MPLW515L induces myeloproliferation characterized by splenomegaly, leukocytosis, marked thrombocytosis, extramedullary hematopoeisis, and myelofibrosis. In addition, a small-molecule JAK kinase inhibitor inhibits proliferation of MPLW515L-transformed cells, suggesting that targeted inhibition of JAK-STAT signaling may be an effective therapy for both JAK2V617F-positive and MPLW515L-positive MPD. 
###end p 63
###begin p 64
###xml 162 172 162 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 366 369 366 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 399 409 399 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 524 532 524 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 618 626 618 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 796 804 796 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 850 860 850 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
Although the constitutively active JAK2V617F mutant kinase is present in many patients with MPD, there are a significant proportion of MF and ET patients who are JAK2V617F-negative. We hypothesized that activation of JAK-STAT signaling in these patients might result from activating mutations in cytokine receptors, which led to the discovery of a novel mutation in MPL ( MPLW515L) in patients with JAK2V617F-negative MF. The mutation is present in granulocytes but not in non-hematopoietic germline DNA, demonstrating that MPLW515L is a somatic mutation present in clonally derived hematopoietic cells. Moreover, the MPLW515L allele was not observed in a panel of normal individuals, demonstrating that it is not a common single nucleotide polymorphism. These data provide genetic evidence that MPLW515L is a pathogenetic mutation in this subset of JAK2V617F-negative MF. 
###end p 64
###begin p 65
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b013">13</xref>
###xml 38 40 38 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b015">15</xref>
###xml 1005 1013 <span type="species:ncbi:9606">patients</span>
In contrast to previous reports [ 13- 15], we have identified a mutant MPL receptor that results in constitutive activation of downstream signal transduction pathways. MPL signals via its association with JAK2 and TYK2, resulting in phosphorylation of both MPL and JAK2/TYK2 and consequent activation of the STAT3, STAT5, ERK/MAPK, and PI3K/AKT signaling pathways. MPLW515L activates JAK-STAT signal transduction independently of ligand binding, and, in contrast with MPLWT, confers cytokine-independent growth to 32D, Ba/F3, and UT7 cells. Moreover, Western blot analysis shows ligand-independent phosphorylation of downstream signaling proteins, which may effect both proliferation and differentiation. Finally, hematopoietic cells that express MPLW515L are hypersensitive to stimulation with TPO as assessed by cell proliferation and Western blot analysis, suggesting MPLW515L-positive hematopoietic progenitors may have a selective proliferative advantage as compared with wild-type progenitors in MF patients. 
###end p 65
###begin p 66
###xml 387 390 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b022">22</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b023">23</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b024">24</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b025">25</xref>
The discovery of this mutation provides a novel mechanism for activation of signal transduction in hematopoietic malignancies. Somatic mutations in MPL have not previously been described, though previous genetic and biochemical data suggest that the cytoplasmic-transmembrane junction (which includes W515) is important in its activation. These data include the germline S505N allele in MPL associated with familial ET [ 22, 23], the W515S mutation that has been reported as a spontaneous mutation in Ba/F3 cells stably transduced with MPL[ 24], and the observation that in vitro deletion of the RWQFP domain that includes W515 results in MPL activation [ 25]. The mechanism of activation of MPL by these alleles is not fully understood, and it will be of value to obtain structural insight into the role of the cytoplasmic transmembrane-junction region in the regulation of MPL signal transduction. 
###end p 66
###begin p 67
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b026">26</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b027">27</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b017">17</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b028">28</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b029">29</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b011">11</xref>
###xml 1290 1292 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b030">30</xref>
###xml 26 32 <span type="species:ncbi:10090">murine</span>
###xml 107 113 <span type="species:ncbi:9606">humans</span>
###xml 257 263 <span type="species:ncbi:9606">humans</span>
###xml 323 329 <span type="species:ncbi:10090">murine</span>
###xml 686 692 <span type="species:ncbi:9606">humans</span>
###xml 772 778 <span type="species:ncbi:10090">murine</span>
###xml 926 931 <span type="species:ncbi:9606">human</span>
###xml 972 976 <span type="species:ncbi:10090">mice</span>
###xml 1038 1044 <span type="species:ncbi:10090">murine</span>
###xml 1059 1064 <span type="species:ncbi:9606">human</span>
###xml 1244 1250 <span type="species:ncbi:10090">murine</span>
###xml 1278 1283 <span type="species:ncbi:9606">human</span>
Expression of MPLW515L in murine bone marrow recapitulated many of the phenotypic characteristics of MF in humans, including atypical megakaryocytic hyperplasia, splenomegaly due to extramedullary hematopoiesis, and thrombocytosis that may be attenuated in humans by splenic sequestration [ 26, 27]. This is in contrast to murine bone marrow transplant experiments with constitutively activated tyrosine kinase alleles evaluated in our laboratory and by others, including TEL-JAK2, FLT3-ITD, and FIP1L1-PDGFRA [ 17, 28, 29], that each result in a neutrophilic MPD without involvement of the megakaryocyte lineage. It is of interest that JAK2V617F, which is associated with ET and MF in humans, results in polycythemia and leukocytosis, but not thrombocytosis, in the same murine BMT model [ 11]. Of note, absolute leukocytosis in both the JAK2V617F and the MPLW515L-mediated BMT models is higher than is typically observed in human PV and MF, respectively. Also, MPLW515L mice develop rapidly fatal disease. These differences between the murine model and the human phenotype are likely accounted for by the retroviral transduction model of disease, and is similar to what has been observed for the rapidly fatal BCR-ABL-mediated disease in the murine BMT model as compared with human CML [ 30]. 
###end p 67
###begin p 68
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b031">31</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b032">32</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b033">33</xref>
###xml 431 434 431 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b034">34</xref>
###xml 161 167 <span type="species:ncbi:10090">murine</span>
###xml 247 253 <span type="species:ncbi:10090">murine</span>
###xml 435 440 <span type="species:ncbi:10090">mouse</span>
###xml 623 628 <span type="species:ncbi:9606">human</span>
MPLW515L-expressing bone marrow and spleen cells exhibit cytokine-independent colony formation, another feature of clinical ET and MF. In addition, the MPLW515L murine bone marrow transplant model shares some phenotypic characteristics with other murine models of MF, including that induced by overexpression of thrombopoietin, either in transgenic [ 31] or in bone marrow transplant models [ 32, 33], and in the transgenic GATA-1 low mouse [ 34], though the severity and chronicity of the MF phenotype varies in these different models, which, unlike the current model, are not based on somatic disease alleles observed in human MF. 
###end p 68
###begin p 69
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b026">26</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b027">27</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b035">35</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030270-b036">36</xref>
###xml 975 984 975 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F</italic>
###xml 1041 1051 1041 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAK2V617F-</italic>
###xml 1081 1089 1081 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 550 558 <span type="species:ncbi:9606">patients</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
###xml 1063 1071 <span type="species:ncbi:9606">patients</span>
###xml 1338 1346 <span type="species:ncbi:9606">patients</span>
MPLW515L is an attractive target for therapeutic intervention with small molecule inhibitors. Current treatments for MF include empiric therapies such as hydroxyurea or interferon, and splenectomy for symptomatic splenomegaly [ 26, 27]. Allogeneic stem cell transplantation is a viable option for some patients with MF, but most patients are diagnosed at an advanced age and are not candidates for stem cell transplantation. Recent clinical trials with thalidomide demonstrated modest efficacy in MF, largely by slowing the rate of fibrosis in these patients rather than by reversal of fibrosis [ 35]. Allogeneic BMT data does indicate that eradication of the malignant hematopoietic clone in MF does result in complete reversal of fibrosis [ 36], and suggests that drugs that target mutant alleles such as MPLW515L may be effective disease-remitting agents. JAK2 inhibitor development is well under way as a potential therapeutic strategy for treating MPD patients with the JAK2V617F allele. Data presented here indicate that the subset of JAK2V617F-negative MF patients with the MPLW515L mutation will also be sensitive to inhibition with small molecule JAK2 inhibitors. These findings also suggest that a more expansive genomic screen for involvement of other components of the JAK-STAT signal transduction pathway is warranted in MPD patients. 
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin title 71
Primer Sequences Used in This Study
###end title 71
###begin p 72
(25 KB DOC)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin title 74
Accession Numbers
###end title 74
###begin p 75
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPL</italic>
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EPOR</italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCSFR</italic>
The UniGene ( ) accession numbers used in this paper are MPL (Hs.82906 and Mm.4864), EPOR (Hs.127826), and GCSFR (Hs.524517). 
###end p 75
###begin p 76
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 698 703 <span type="species:ncbi:10090">mouse</span>
YP is a Research Training Fellow of the Howard Hughes Medical Institute. DGG is a Doris Duke Foundation Distinguished Clinical Scientist and an Investigator of the Howard Hughes Medical Institute. TRG is an Investigator of the Howard Hughes Medical Institute. TM is a recipient of a Special Fellow Award from the Leukemia and Lymphoma Society. MW is a recipient of an American Society of Clinical Oncology Young Investigator Award. We thank the patients who participated in this study and Joyce Niblack, JD, for support and access to the mpdinfo.org (Myeloproliferative Disorders) Web site. We are indebted to Allison Coburn, Rachel Okabe, and Dana Cullen for assistance with sample processing and mouse work, to Tarrah Kirkpatrick and Arnold Gonzales for assistance with the MPD study, and to Alexis Bywater for technical and administrative assistance.
###end p 76
###begin p 77
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. YP, DGG, and RLL designed the study and wrote the manuscript. YP, BHL, TM, BLE, and RLL performed research and analyzed data. BHL and TM contributed to writing the manuscript. EMD, MG, AC, JJC, and MW performed research. SM provided technical assistance. IG, DJD, and JJC organized the collection of samples at Dana-Farber Cancer Institute. GW, SJL, TRG, and MW contributed to study design. 
###end p 77
###begin title 78
References
###end title 78
###begin article-title 79
Some speculations on the myeloproliferative syndromes
###end article-title 79
###begin article-title 80
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
###end article-title 80
###begin article-title 81
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
###end article-title 81
###begin article-title 82
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
###end article-title 82
###begin article-title 83
###xml 49 54 <span type="species:ncbi:9606">human</span>
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
###end article-title 83
###begin article-title 84
A gain-of-function mutation of JAK2 in myeloproliferative disorders
###end article-title 84
###begin article-title 85
###xml 218 226 <span type="species:ncbi:9606">patients</span>
X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis
###end article-title 85
###begin article-title 86
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
###end article-title 86
###begin article-title 87
Identification of an Acquired JAK2 Mutation in Polycythemia Vera
###end article-title 87
###begin article-title 88
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
###end article-title 88
###begin article-title 89
###xml 99 105 <span type="species:ncbi:10090">murine</span>
Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
###end article-title 89
###begin article-title 90
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders
###end article-title 90
###begin article-title 91
Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L
###end article-title 91
###begin article-title 92
###xml 68 73 <span type="species:ncbi:9606">human</span>
Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies
###end article-title 92
###begin article-title 93
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Molecular analysis of erythropoietin receptor system in patients with polycythaemia vera
###end article-title 93
###begin article-title 94
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
###end article-title 94
###begin article-title 95
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 128 134 <span type="species:ncbi:10090">murine</span>
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
###end article-title 95
###begin article-title 96
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo
###end article-title 96
###begin article-title 97
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
###end article-title 97
###begin article-title 98
The International HapMap Project
###end article-title 98
###begin article-title 99
Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor
###end article-title 99
###begin article-title 100
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
###end article-title 100
###begin article-title 101
An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia
###end article-title 101
###begin article-title 102
A novel MPL point mutation resulting in thrombopoietin-independent activation
###end article-title 102
###begin article-title 103
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor
###end article-title 103
###begin article-title 104
Pathogenesis of myelofibrosis with myeloid metaplasia
###end article-title 104
###begin article-title 105
Myelofibrosis with myeloid metaplasia
###end article-title 105
###begin article-title 106
STAT5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
###end article-title 106
###begin article-title 107
###xml 45 51 <span type="species:ncbi:10090">murine</span>
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease
###end article-title 107
###begin article-title 108
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
###end article-title 108
###begin article-title 109
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 31 37 <span type="species:ncbi:10090">murine</span>
Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis
###end article-title 109
###begin article-title 110
###xml 101 105 <span type="species:ncbi:10090">mice</span>
High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice
###end article-title 110
###begin article-title 111
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice
###end article-title 111
###begin article-title 112
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Development of myelofibrosis in mice genetically impaired for GATA-1 expression ( GATA-1(low) mice) 
###end article-title 112
###begin article-title 113
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial
###end article-title 113
###begin article-title 114
Allogeneic hematopoietic stem cell transplantation for myelofibrosis
###end article-title 114
###begin title 115
Abbreviations
###end title 115
###begin p 116
erythropoietin receptor
###end p 116
###begin p 117
essential thrombocytosis
###end p 117
###begin p 118
###xml 6 12 <span type="species:ncbi:9913">bovine</span>
fetal bovine serum
###end p 118
###begin p 119
granulocyte-colony stimulating factor receptor
###end p 119
###begin p 120
hematoxylin and eosin
###end p 120
###begin p 121
myelofibrosis with myeloid metaplasia
###end p 121
###begin p 122
myeloproliferative disorders
###end p 122
###begin p 123
thrombopoietin receptor
###end p 123
###begin p 124
polycythemia vera
###end p 124
###begin p 125
thrombopoietin
###end p 125
###begin title 126
Figures and Tables
###end title 126
###begin title 127
MPLW515L Mutation Is Found in JAK2V617F-Negative MF and Causes Cytokine-Independent Growth in 32D and UT7 Cells, and Constitutively Activates the JAK-STAT Signaling Pathway
###end title 127
###begin p 128
###xml 173 180 <span type="species:ncbi:9606">patient</span>
###xml 246 253 <span type="species:ncbi:9606">patient</span>
(A) Forward (middle trace) and reverse (lower trace) sequence traces demonstrating a heterozygous guanine to thymine substitution (arrows) present in granulocyte DNA from a patient with MF. The mutation is not present in buccal DNA from the same patient (upper trace).
###end p 128
###begin p 129
(B) DNA sequence and protein translation for both the wild-type and mutant MPL alleles. The mutation results in a tryptophan-to-leucine substitution at codon 515.
###end p 129
###begin p 130
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Upper:</italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lower:</italic>
(C) Upper: 32D cells transduced with MPLW515L exhibit cytokine-independent growth compared with MPLWT (left). Cell lines grown in the presence of IL3 show equal rates of growth (right). Error bars denote the standard deviation for each sample measured in triplicate. Lower: UT7 cells transformed with MPLW515L exhibit cytokine-independent growth compared with MPLWT (left). Cell lines grown in the presence of TPO (5 ng/mL) show equal rates of growth (right). Error bars denote the standard deviation for each sample measured in triplicate. 
###end p 130
###begin p 131
(D) 32D cells, 32D MPLWT cells, and 32D MPLW515L cells were deprived of cytokines and then analyzed by Western blots, demonstrating phosphorylation of JAK2, STAT5, STAT3, AKT, and ERK in MPLW515L compared with MPLWT.
###end p 131
###begin title 132
MPLW515L-Expressing Cells Show Hyper-Responsiveness to TPO
###end title 132
###begin p 133
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
(A) 32D MPLWT cells and 32D MPLW515L cells were cultured in triplicate at an initial concentration of 1 x 10 5 cells/mL, in RPMI/10% FBS containing TPO 2 ng/mL, 1 ng/mL, 0.1 ng/mL, 0.01 ng/mL, 0.001 ng/mL, or in the absence of TPO for four days, and then cell numbers were assessed. Error bars denote the standard deviation for each sample measured in triplicate. 
###end p 133
###begin p 134
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
(B) UT7 MPLWT cells and UT7 MPLW515L cells were cultured in triplicate, at an initial concentration of 1 x 10 5 cells/mL, in IMDM/10% FBS containing TPO 5 ng/mL, 1 ng/mL, 0.1 ng/mL, 0.01 ng/mL, 0.001ng/mL, or in the absence of TPO for six days, and then cell numbers were assessed. Error bars denote the standard deviation for each sample measured in triplicate. 
###end p 134
###begin p 135
(C) 32D MPLWT or 32D MPLW515L cells were deprived of cytokine overnight and then stimulated with TPO 5 ng/mL, 1 ng/mL, 0.1 ng/mL, 0.01 ng/mL, or without TPO for seven minutes and then analyzed by Western blot for phosphorylation of JAK2 and STAT3, demonstrating increased JAK2/STAT3 phosphorylation in response to TPO in 32D MPLW515L cells as compared with 32D-MPLWT cells.
###end p 135
###begin p 136
(D) Phosphorylation of JAK2, TYK2, STAT3, STAT5, AKT, and ERK in response to seven-minute stimulation with TPO (50ng/mL). 32D MPLWT or 32 MPLW515L cells were deprived of cytokine overnight and then stimulated with TPO 50 ng/mL for seven minutes and then analyzed by Western blot for phosphorylation of JAK2, TYK2, STAT3, STAT5, AKT, and ERK, demonstrating increased phosphorylation of these proteins in response to TPO in 32D MPLW515L cells as compared with 32D MPLWT cells.
###end p 136
###begin title 137
Bone Marrow Transplant with MPLW515L-Transduced Bone Marrow Causes a Rapid Myeloproliferative Disease
###end title 137
###begin p 138
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
(A) Kaplan-Meier survival plot of Balb/C mice transduced with MPLW515L ( n = 9) and MPLWT ( n = 6) showing death of all MPLW515L mice between 17 and 32 days post-BMT compared with MPLWT ( n = 6), which were sacrificed for endpoint analysis without evidence of disease. 
###end p 138
###begin p 139
(B) Complete blood counts show leukocytosis and thrombocytosis in MPLW515L BMT model compared with MPLWT. There is no difference in hematocrits. Standard deviation is indicated.
###end p 139
###begin p 140
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
(C) Spleen weights of MPLW515L and MPLWT mice shows splenomegaly in MPLW515L mice but not in MPLWT mice with average spleen weight equal to 1,171 mg.
###end p 140
###begin p 141
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
(D) Liver weights of MPLW515L and MPLWT mice shows hepatomegaly in MPLW515L mice but not in MPLWT mice, with average liver weight equal to 2,390 mg (compared with 1,222 mg in MPLWT mice).
###end p 141
###begin p 142
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
(E) Bone marrow shows significantly increased bone marrow fibrosis by reticulin staining at 17 days post-BMT in MPLW515L mice, but not in MPLWT-expressing mice.
###end p 142
###begin title 143
MPLW515L and MPLWT Bone Marrow Transplant Model Histopathology
###end title 143
###begin p 144
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 1155 1159 <span type="species:ncbi:10090">mice</span>
###xml 1631 1635 <span type="species:ncbi:10090">mice</span>
Histology of MPLW515L-transduced and MPLWT-transduced Balb/C mice showing images of peripheral blood (A and B) and histopathology in representative sections of bone marrow (C and D), spleen (E-H), and liver (I-L). Peripheral blood smear (B) (600x, Wright-Giemsa) of a representative MPLWT animal displays an unremarkable white blood cell and platelet count. In contrast, peripheral blood smear (A) (600x, Wright-Giemsa) of a representative MPLW515L mutant animal reveals marked thrombocytosis and leukocytosis comprising a predominant population of maturing myeloid cells as well as frequent nucleated erythroid forms. Bone marrow images from MPLWT animals display preserved marrow architecture with maturing trilineage hematopoiesis (D) (600x, hematoxylin and eosin [H&E]). Comparatively, bone marrow sections from MPLW515L mutant animals demonstrate marrow elements comprising a prominent population of maturing myeloid cells with increased numbers of megakaryocytes including atypical and dysplastic forms occurring in frequent clusters (C) (600x, H&E) and showing emperipolesis of neutrophils in megakaryocyte cytoplasm. Spleen sections from MPLW515L mice display complete effacement of normal splenic architecture (E) (40x, H&E) with a marked expansion of red pulp that is composed of an admixture of maturing myeloid and erythroid elements and numerous numbers of atypical megakaryocytes (G) (600x, H&E) compared with MPLWT spleens (F and H) (40x and 600x, H&E), which display a relative preservation of normal spleen architecture and the presence of only maturing erythroid forms in the red pulp. Liver images from MPLW515L mice illustrate evidence of extensive extramedullary hematopoiesis in a perivascular and sinusoidal distribution (I) (100x, H&E) composed predominantly of a population of maturing erythroid elements with frequent large atypical megakaryocytes and occasional admixed myeloid forms (K) (600x, H&E). In comparison, only small, focal areas of nucleated erythroid cells were observed in livers from MPLWT animals (J and L) (100x and 600x, H&E).
###end p 144
###begin title 145
###xml 44 48 <span type="species:ncbi:10090">Mice</span>
Flow Cytometry Analysis of BM and Spleen in Mice Transduced with MPLW515L and MPLWT
###end title 145
###begin p 146
(A) Flow-cytometry analysis of bone marrow cells shows a 4-fold increase in Mac1+/Gr1+ cells and a shift to a more immature erythroid population. There is a 15-fold increase in CD41+ cells in bone marrow expressing MPLW515L compared with MPLWT.
###end p 146
###begin p 147
(B) Flow-cytometry analysis of spleen cells shows a 10-fold increase in Mac1+/Gr1+ cells in MPLW515L. There is also a shift to a more immature erythroid population in MPLW515L with a greater percentage of CD71+/Ter119- cells. CD41+ cells are increased 30-fold in MPLW515L spleen cells compared with MPLWT spleen cells.
###end p 147
###begin title 148
MPLW515L Increases the Number of Megakaryocyte and Myeloid Colonies in Spleen, without Affecting Megakaryocyte Ploidy, and Causes Cytokine-Independent Myeloid Colony Growth
###end title 148
###begin p 149
(A) Megakaryocyte colony-forming assay in the presence of TPO, IL3, IL11, and IL6 demonstrates similar numbers of megakaryocyte colonies obtained from MPLW515L-expressing bone marrow and an increase in the number of megakaryocyte colonies from spleen cells compared with MPLWT.
###end p 149
###begin p 150
(B) Acetylcholinesterase staining of megakaryocyte colonies derived from bone marrow demonstrates much larger colony size in MPLW515L as compared with MPLWT megakaryocyte colonies.
###end p 150
###begin p 151
(C) Megakaryocyte ploidy analysis shows the same distribution for MPLW515L-expressing cells and MPLWT-expressing cells.
###end p 151
###begin p 152
###xml 398 406 398 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030270-g006">Figure 6</xref>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
(D and E) Total myeloid colony formation from bone marrow cells (D) and spleen cells (E) demonstrates cytokine-independent colony formation in MPLW515L bone marrow and spleen. There is no difference in colony distribution between MPLWT- and MPLW515L-expressing cells. Colony counts reflect only positively identifiable colonies, with thorough megakaryocyte colony analysis done in MegaCult assay ( Figure 6A), and thus are excluded from methylcellulose colony analysis. Colony numbers represent a total of three representative mice per group, in duplicate. 
###end p 152
###begin title 153
32D MPLW515L Cells Are Sensitive to JAK Inhibitor I
###end title 153
###begin p 154
(A) Dose-dependent inhibition of growth of 32D MPLW515L and 32D MPLWT cells but not 32D FIP1L1-PDGFRA cells with increasing doses of JAK Inhibitor I.
###end p 154
###begin p 155
(B) Reduction in STAT3 phosphorylation in 32D MPLW515L cells but not 32D FIP1L1-PDGFRA cells with increasing doses of JAK Inhibitor I. Cells were incubated with varying drug concentrations for four hours and then collected for Western blot analysis.
###end p 155
###begin p 156
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MPLW515L</italic>
Citation: Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3(7): e270. DOI: 10.1371/journal.pmed.0030270 
###end p 156
###begin p 157
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: Supported in part by National Institutes of Health grants DK50654 and CA66996 to DGG and by the Leukemia and Lymphoma Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 
###end p 157

